Form NT 10-Q bluebird bio, Inc. For: Jun 30
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Oppenheimer Reiterates Perform Rating on bluebird bio (BLUE)
August 15, 2024 7:05 AM EDTOppenheimer analyst Mark Breidenbach reiterated a Perform rating on bluebird bio (NASDAQ: BLUE).
The analyst comments "While the company has excelled in its ability to activate qualified treatment centers (QTCs)with over 70 centers activated in the U.S., beyond its goal of 40 to 50, the number... More
JPMorgan Downgrades bluebird bio (BLUE) to Neutral
August 14, 2024 4:21 PM EDTJPMorgan analyst Eric Joseph downgraded bluebird bio (NASDAQ: BLUE) from Overweight to Neutral.
The analyst comments "Were downgrading BLUE shares to N from OW following the 2Q results update. Of note, product sales of $16.1M missed street estimates by ~$6M (BBG consensus estimate of $22.6M; JPMe: $17.4M), implying 8 Zynteglo and 1 Skysona treated patients in the quarter. Despite the company noting steady commercial progress across the cell therapy portfolio in 2Q, FY24 commercial guidance was... More
